Atomwise’s AIMS (Artificial Intelligence Molecule Screening) project has demonstrated significant potential to accelerate drug discovery. In a landmark multiyear study published in Nature Scientific Reports, the project used Atomwise’s AI platform, AtomNet, to successfully identify structurally novel compounds across a diverse range of therapeutic targets. In the virtual high-throughput screening (HTS) study, AtomNet analyzed 318…
Forget efficiency, focus on shifting the standard of care with AI in drug discovery
Much has been made about AI’s potential to accelerate drug development timelines while chipping away at its often multi-billion-dollar price tag. But Abraham Heifets, CEO of Atomwise, believes that focusing on efficiency is not necessarily the right measure — or the right conversation — to have. Time for a different conversation “The two ways to…
10 pioneering companies implementing AI in drug discovery, development and beyond
The pharma industry is embracing artificial intelligence (AI) to streamline drug discovery and development, although adoption remains early. The field, however, is rapidly expanding. The global AI in drug discovery market was worth about $1.1 billion last year but could grow at a 30% clip from 2023 to 2030, according to Grand View Research. In…